Previous Article | Next Article ![]()
Journal of Clinical Microbiology, July 2000, p. 2602-2610, Vol. 38, No. 7
ClinCyte, LLC, San Diego, California
921211; Department of Veterinary
Pathobiology, College of Veterinary Medicine, Texas A&M University,
College Station, Texas 77843-44672;
Department of Veterinary Science, School of Veterinary
Medicine, Louisiana State University, Baton Rouge, Louisiana
708033; Division of Zoonotic Disease
Research, National Animal Disease Center, U.S. Department of
Agriculture, Ames, Iowa 500104;
Department of Genetics and Plant Breeding, University of
Agricultural Sciences, Bangalore, India 5600655;
and Institute of Animal Health and Veterinary Biologicals,
Hebbal, Bangalore, India 5600246
Received 19 October 1999/Returned for modification 29 December
1999/Accepted 13 April 2000
A multiplex amplification and detection platform for the diagnosis
of Mycobacterium bovis and Brucella abortus
infection simultaneously in bovine milk and nasal secretions was
developed. This system (designated the bovine pathogen detection assay
[BPDA]-PCR) consists of duplex amplification of species-specific
targets (a region of the BCSP31K gene of B. abortus and a
repeat-sequence region in the hsp65 gene of M. bovis, respectively). This is followed by a solid-phase probe
capture hybridization of amplicons for detection. On the basis of
spiking experiments with normal milk, the analytical sensitivity of the
assay was 800 CFU equivalents/ml of milk for B. abortus and
as low as 4 CFU equivalents per ml of milk for M. bovis.
BPDA-PCR was validated with 45 liver samples from lemmings
experimentally infected with B. abortus. The assay sensitivity, based on culture status as a "gold standard," was 93.9%. In this experiment, BPDA-PCR also identified five
culture-negative liver samples as positive (41.7%). Field studies for
the evaluation of BPDA-PCR were performed with samples from dairy
animals from geographically distinct regions (India, Mexico, and
Argentina). A high prevalence of shedding of B. abortus
(samples from India) and M. bovis (samples from Mexico) was
identified by BPDA-PCR. In samples from India, B. abortus
shedding was identified in 86% of milk ring test-positive animals
(n = 15) and 80% of milk ring test-negative cows
(n = 5). In samples from Mexico, M. bovis was identified by PCR in 32.6% of pools
(n = 46) of milk that each contained milk from 10 animals and in 56.2% of nasal swabs (n = 121) from
cattle from tuberculin test-positive herds. In contrast, the Argentine
cattle (n = 70) had a modest prevalence of M. bovis shedding in nasal swabs (2.9%) and milk (1.4%) and of
B. abortus in milk (11.4%). On the basis of these
analyses, we identify BPDA-PCR as an optimal tool for both screening of
herds and testing of individual animals in a disease eradication
program. A combination of the duplex assay, screening of milk samples
in pools, and the proposed algorithm provides a highly sensitive,
cost-effective, and economically viable alternative to serological testing.
Animal health and human health are
inextricably linked. For millennia, humans have depended on animals for
nutrition, socioeconomic development, and companionship (1).
Yet animals can transmit many different but potentially devastating
diseases to humans.
Brucellosis is a zoonosis of both public health and economic importance
in many developing countries (5, 24). Six species of
Brucella are presently known: B. abortus,
B. suis, B. melitensis, B. ovis,
B. neotomae, and B. canis (1, 24).
Brucellosis has been effectively controlled in many developed or
industrialized nations, thereby reducing the number of cases of
brucellosis among humans (5). Despite the preventive and
control measures that exist in developed nations, there is still a high
potential for transmission and spread of brucellae via animal products
imported from developing nations (1). Thus, animal
brucellosis poses a barrier for trade of animals and animal products
and could seriously impair socioeconomic progress in the developing
world (19, 20, 37).
Official estimates put losses due to brucellosis in Latin America
equivalent to about US$600 million annually, which explains the
priority given by animal health services to reducing the incidence of
the disease (5). The World Health Organization reports an annual incidence of brucellosis in people of less than 1 to 78 cases
per 100,000 population in the Middle East, with six countries reporting
an annual total incidence of over 90,000 cases. Among the Latin
American countries, Argentina reports the largest incidence, followed
by Mexico and Peru (5, 37). Although brucellosis is a
notifiable disease in many countries, official figures do not fully
reflect the number of cases reported annually, and the true incidence
has been estimated to be between 10 and 25 times higher than what the
reported figures indicate (5).
Currently, identification of brucella-infected animals is based on
either the milk ring test, enzyme-linked immunosorbent assay (ELISA),
or some PCR-based tests (on an experimental basis only) (2, 32,
33, 36). In addition, reports of brucellosis in free-ranging
bison in Yellowstone National Forest and the need to diagnose such
infections rapidly and unambiguously (to prevent potential spillover of
infection to domestic animal populations) reemphasize the necessity for
the development of a molecular biology-based assay.
One-third of the world's human population is infected with
Mycobacterium tuberculosis, and 3 million human deaths
annually are attributable to the organism (1, 6). The
pulmonary form of zoonotic tuberculosis (TB) caused by
Mycobacterium bovis in humans is indistinguishable from the
TB caused by M. tuberculosis (strict sense) (7, 8,
31). Both species belong to the M. tuberculosis
complex group, which includes Mycobacterium microti and
Mycobacterium africanum (31). The four species
are closely related at the genetic level (with 95% DNA-DNA homology)
and are considered host specialists (31) on the basis of
their ability to cause disease in limited host populations. However,
M. bovis (considered the ancestral variant of the other
three species) has the widest host range including animals and humans
(1, 31). Hence, animal TB poses a potential source of TB in
humans. In countries where bovine TB is uncontrolled, most human cases occur in young persons and result from the drinking or handling of
contaminated milk or milk products (1, 7, 8). Little is
known about the frequency of involvement of M. bovis in
nonpulmonary TB in the developing nations because of limited laboratory
facilities for the culture and identification (or typing) of tubercle
bacilli (7; F. Miolan-Suazo, M. Salman, J. Payeur,
C. Ramirez, and J. Rhyan, Proc. U.S. Anim. Health Assoc. Meeting,
Tuberculosis session, p. 51-61, 1997).
Information on the incidence of human disease due to M. bovis in developed and developing countries is scarce. A review of zoonotic TB from 1954 to 1970 estimated that the proportion of cases
due to M. bovis accounted for 3.1% of all forms of TB:
2.1% of pulmonary forms and 9.4% of extrapulmonary forms
(7). The use of direct smear microscopy as the only method
for diagnosis of suspected TB, a requirement of any national TB
program, may partly explain the relatively low rate of notification of
disease due to M. bovis in developing countries
(7). Direct smear microscopy (in addition to its low
sensitivity) does not permit differentiation between species of the
M. tuberculosis complex; in addition, culture and species
assignment, even when carried out, are time-consuming and not
confirmatory for the accurate identification of M. bovis (7, 16). Currently, animal TB is diagnosed by a skin
test that includes a caudal fold, comparative cervical, single
cervical, or double-strength cervical test (1, 14;
Miolan-Suazo et al., Proc. USAHA Meeting). The skin test has a low
sensitivity (65.6 to 70%) (25; Miolan-Suazo, Proc.
USAHA Meeting). Although some reports suggest that skin tests have a
high specificity (98.8%) (25), false-positive results due
to exposure to atypical mycobacteria, corynebacteria, Fasciola
hepatica (liver fluke), and/or nocardia species are problematic in
some countries. Alternate tests including ELISA, lymphocyte stimulation
tests, gamma interferon assay (35), and blood tuberculosis
battery tests are useful but are complementary to skin tests rather
than real alternatives (25; Miolan-Suazo et al.,
Proc. USAHA Meeting).
In the absence of a highly sensitive and specific diagnostic assay,
prevention and control of these zoonoses is dependent on the control
and eradication of infection in animals, because the transmission of
these diseases is primarily from animals to humans and is seldom
between humans. This in turn is dependent upon a rapid, yet sensitive
and specific means of detection of brucellae or M. bovis
organisms in potentially infective materials such as milk or nasal
swabs. In this study we describe a duplex amplification assay that can
identify one or both organisms in a single reaction. The assay
described herein is designed for milk samples and nasal swabs but can
easily be expanded to test other samples such as lymph node aspirates,
aborted fetal tissues, placental fluids or placenta from aborted cows,
lungs or lung lesions collected at necropsy, and nasal aspirates.
Bacterial strains. (i) B. abortus.
Purified
genomic DNAs from two bovine isolates (isolates NADC 8-1070 and NADC
8-0840), two vaccine strains (strains RB51 and S19), and one type
strain (strain 544) of B. abortus (3) were obtained from the collection of the National Animal Disease Center (NADC), Ames, Iowa, for development of the assay.
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
A Multiplex Approach to Molecular Detection of Brucella
abortus and/or Mycobacterium bovis Infection
in Cattle
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(ii) M. tuberculosis complex. Whole-cell lysates enriched with genomic DNA from 15 M. bovis strains and prepared with a mini-bead beater (15) were a generous gift from the Tuberculosis Laboratory of the Centers for Disease Control and Prevention, Atlanta, Ga. This set included 11 field isolates of M. bovis, characterized on the basis of oxyR285 polymorphism (30), and four strains of M. bovis BCG from the Trudeau Medical Collection (strains TMC1010, TMC1002, TMC1029, and TMC1012). Six M. tuberculosis (strict sense) isolates that had been characterized on the basis of IS6110 fingerprints and for mutations in certain drug resistance-associated genes (rpoB, katG, and pncA) were obtained from the Public Health Research Institute, New York, N.Y., and were analyzed in this study.
A freeze-dried vaccine strain of BCG was used in spiking and serial dilution experiments to define assay parameters.Negative milk samples. A total of 10 raw milk samples were obtained from a local herd in Colorado with no history of brucellosis or tuberculosis. The 10 samples were PCR tested for true-negative status. These samples were used in all spiking experiments and in the entire study as negative controls for PCR with milk.
The optical densities (ODs) of 63 negative samples (including negative milk samples from a local disease-free herd [n = 10], samples from a disease-free herd from Argentina [n = 16], PCR-negative controls [n = 27], and amplicons generated from Ehrlichia equi [n = 2], and Babesia microti [n = 2], and drug resistance-associated gene-sequence regions from M. tuberculosis [two amplicons each; katG, rpoB, and pncA]) were used to define a negative cutoff value (negative mean ± 3 standard deviations).DNA extraction (milk). In this study, DNA was extracted by using a 1-ml aliquot of milk with a Boom extraction modification of a QIAamp Blood and Tissue DNA Extraction protocol (34). Briefly, 1 ml of milk was centrifuged at 6,000 × g for 10 min. The clear whey portion was suctioned out with a transfer pipette and discarded. The remaining milk solids and butterfat were used for further processing and DNA extraction. Preheated sterile, double-distilled, deionized water was used to bring the volume of the samples to 200 µl, and the mixture was vigorously vortexed to release the pellet from the bottom of the tube. A total of 25 µl of proteinase K (a 20-mg/ml stock) was added, and the mixture was vortexed to mix. Subsequently, 200 µl of preheated lysis buffer was added to each tube, and the contents were vortexed again until the mixture was homogeneous. The mixture was then incubated at 70°C for 30 min. A second aliquot of proteinase K was added, and the mixture was incubated at 70°C for an additional 30 min. After incubation, 210 µl of ethanol was added, the mixture was vortexed, and the samples were processed to DNA through QIAamp columns (catalog no. 29106; Qiagen, Valencia, Calif.) as described in the product insert (QIAamp Blood and Body Fluids protocol; Qiagen). DNA was eluted in 200 µl of sterile, double-distilled, deionized water in all cases except where specified.
B. abortus (31-kDa protein or BCSP31K gene region). The gene that encodes the 31-kDa protein is well conserved within the genus Brucella, with stretches of nucleotide sequences that are species specific. A 311-bp region of the BCSP31K gene (GenBank accession no. M20404) with four B. abortus-specific regions was identified. The primers located at nucleotides 844 to 864 (5'-ACGCAGTCAGACGTTGCCTAT-3') and nucleotides 1154 to 1131 (5'-TCCAGCGCACCATCTTTCAGCCTC 3') amplify a B. abortus-specific region (311 bp). A B. abortus-specific probe was designed by using this amplicon sequence and a series of GenBank database searches. The design involved combination of two regions within the amplicon so as to be able to capture both sense and antisense strands of the amplicon. The probe used was 5'-CGACGATGGTGCCAGAAGATTTGCGCCTTCTG-3' (nucleotides 1035 to 1048 and 910 to 927). Since database searches indicated that both the amplification primers and the probe were unique to B. abortus, this region was used for assay development.
M. tuberculosis complex (putative host cell receptor binding protein [a segment of hsp65 gene with a region of direct-repeat sequences]). The hsp65 gene is well conserved within the M. tuberculosis complex group and has stretches of specific nucleotide sequences that can be used as probes. A direct-repeat segment in hsp65 gene (GenBank accession no. S46909) that contains four regions specific for the M. tuberculosis complex was identified. The primers for one such region located at nucleotides 272 to 293 (5'-GGCTGGTTACACCTTCGATGCG-3') and nucleotides 618 to 601 (5'-AGCCGCCGAAACCCATCT-3') amplify an M. tuberculosis complex-specific region (347 bp). From this amplicon sequence two M. tuberculosis complex-specific regions were identified by database searches. These regions could serve as a probe for the duplex assay. An M. tuberculosis complex-specific probe was designed to capture both sense and antisense strands of the amplicon. The probe sequence identified was 5'-ACATCGGCAACAACAACATCGGC-TGCCGGTGTTGCCGCT-3' (nucleotides 406 to 426 and 506 to 488). The probes have more than one homologous site within the 347-bp amplicon and may enhance the probability of successful hybridization even under very high stringency conditions. Since BLAST database searches indicated that both the amplification primers and probes were unique to M. tuberculosis complex, this region was used for the assay development.
Internal standard (bovine
2-microglobulin).
An internal amplification control was designed and used with all
samples to assess the integrity of DNA (during transport at room
temperature) and the absence (or presence) of PCR inhibitors in the
sample. A 226-bp stretch of the bovine
2-microglobulin sequence (GenBank accession no. X69804) was used as an internal standard. Specific forward and reverse primer sequences at
nucleotides 135 to 155 (5'-ACCTGAACTGCTATGTGTATG-3') and
nucleotides 360 to 340 (5'-TCTCGATCCCACTTAACCTATC-3'),
respectively, were identified by database searches, as
described above for the other two targets. A
2-microglobulin probe (nucleotides 207 to 240;
5'-TTAAATCGGAGCAGTCAGACCTGTCTTTCAGCAA-3') was also designed
for the solid-phase detection assay.
Duplex amplification. Experiments for amplification of either M. bovis alone, B. abortus alone, or the two organisms in combination were performed with genomic DNA purified from the respective bacterial cultures. All four primers used in the amplification reactions were biotinylated. The amplification conditions and master-mixture components (MgCl2 concentration and primer concentrations) were optimized to amplify all DNAs as singlets or in 15 different combinations of B. abortus and M. bovis as duplexes. The master-mixture composition used for a 50-µl reaction mixture was 10× PCR buffer (with 15 mM MgCl2; Perkin-Elmer, Branchburg, N.J.), deoxynucleoside triphosphates (final concentration, 200 µM; Pharmacia), M. tuberculosis complex-specific sense and antisense primers (final concentration, 1 µM), B. abortus-specific primers (final concentration, 0.25 µM), 2.5 µl of genomic DNA from pure bacterial cultures (10 µl of DNA was used for extracts from all primary clinical samples including nasal swabs, lymph nodes, vaginal swabs, and milk), and Taq polymerase (2.5 U per reaction mixture). The thermal cycler parameters used for amplification were initial denaturation at 95°C for 2 min, followed by 35 cycles of denaturation at 94°C for 15 s, annealing at 62°C for 20 s, and extension at 72°C for 20 s. At the end of 35 cycles, a final extension step at 72°C for 7 min was performed.
Solid-phase hybridization and detection. The species-specific probes were designed to target a well-conserved region within the amplicon of interest. The specificities of the probes were identified by a series of GenBank database searches. Each probe was resuspended in freshly prepared 1 M ammonium acetate solution (pH 7.5). M. tuberculosis complex-specific probe was used at a concentration of 50 ng/100 µl, while the B. abortus-specific probe was used at 75 ng/100 µl. For screening for both pathogens in one well, both probes were added in one solution at the concentrations indicated above. For the detection of individual pathogens, only one specified probe was used per coating solution. Each well of the microtiter plates was coated with 100 µl of the solution that contained the probes, and the plates were incubated at 37°C overnight. After overnight incubation, the plates were washed twice with phosphate-buffered saline (PBS)-Tween 20 and were then blocked with PBS-1% bovine serum albumin for 2 h at 37°C. The plates were washed twice with PBS-Tween 20, air dried, and stored in airtight sachets with desiccant at 4°C until they were used.
On the basis of a series of optimization experiments with different salts (guanidium thiocyanate or sodium thiocyanate [NaSCN]) and concentrations (1 and 2.5 M) for hybridization, 1 M NaSCN (pH 5.0 ± 0.2) was identified as the ideal neutralization-hybridization buffer for the duplex detection protocol. Briefly, 25-µl aliquots of the denatured amplicons were loaded into precoated microtiter plate wells that contained 100 µl of hybridization buffer (1 M NaSCN). The plates were incubated at 37°C for 1 h. The plates were then washed five times with PBS-Tween 20. A 100-µl aliquot of a 1:2,500 dilution of neutravidin-peroxidase (Pierce) was added to each well, and the plate was incubated for 15 min at 37°C. The plates were washed seven times with PBS-Tween 20, and 100 µl of tetramethylbenzidine (Moss Inc., Pasadena, Md.) was added to each well. The plates were incubated in the dark for 10 min at room temperature. The reaction was stopped with 5% sulfuric acid (100 µl/well), and the plates were read at 450 nm with an automated ELISA Reader (Bartels Prima System; Baxter Scientific). The background and nonspecific reactivities were tested by using negative controls that consisted of the amplification reaction mixture, amplicons that targeted other drug resistance-associated regions in M. tuberculosis (katG, pncA, rpoB), and 16S rRNA amplicons from other organisms such as B. microti and E. equi. These served as within-species and other extraneous negative controls.Field studies.
The sources of the field samples for these
studies are described in Table 1. Animals
from brucella buffered antigen plate agglutination test- or caudal fold
test-positive and -negative herds from a variety of geographic
localities were sampled (Table 1) and were analyzed by the bovine
pathogen detection assay (BPDA)-PCR. The samples included milk
(n = 136), nasal swabs (n = 149), lymph nodes aspirates (n = 7), and other specimens
(n = 9).
|
(i) Herd sampling in Argentina.
A total of 128 bovine
samples were obtained from farms that were classified as either
"brucellosis positive" (defined by reactivity in a buffered plate
antigen assay), "TB positive" (defined by delayed
hypersensitivity to an intradermal injection of purified protein
derivative), or disease-free (defined by a negative skin test and a
negative buffered plate antigen assay result). The samples included
milk (n = 70), nasal swabs (n = 28),
retropharyngeal lymph node aspirates (m = 7), and
historical samples from a slaughterhouse (vaginal and lymph node swabs)
(n = 9). Fourteen pools of five individual milk samples
each were also analyzed. Table 2 gives the stratified sampling scheme used for this study.
|
(ii) Samples from TB-positive herds in Mexico. Two bovine TB-suspect herds (considered heavily infected, as indicated by caudal fold test results) were sampled. Nasal swabs (n = 121) and milk samples (n = 460) were collected. The milk samples were pooled into batches of 10 milk samples each, and the DNA was analyzed at the ClinCyte laboratory.
(iii) Bovine brucellosis-positive milk samples from India. Milk was sampled from 20 dairy cows either positive (n = 15) or negative (n = 5) for brucellosis as determined by the milk ring test. DNA was extracted in a local laboratory and was analyzed by BPDA-PCR at the ClinCyte laboratory.
Milk collection technique. All milk samples were obtained from animals during their routine milking time. This approach prevented disruption of farmers' day-to-day on-farm operations and simplified sample collection. The samples from each animal were obtained from all four quarters of the mammary gland. Collections were done after thorough disinfection of the teat area with povidone iodine. The milk sampler's (veterinarian's) gloves were also disinfected and wiped dry between samplings. Two to three strippings of milk from each teat were drawn into a sterile 50-ml tube, and the tubes were capped and stored on ice until further use. The entire collection process involved only two technicians (one who collected the milk and one who assisted) to rapidly obtain samples from the 16 to 24 animals in the entire milking shed at a time.
Nasal swab collections. Animals were individually restrained in a trevis or chute with a nose ring, which kept their necks extended. Both nasal passages of each animal were swabbed. Sterile applicators were applied deep into the nostrils, the nostril was vigorously scrubbed two to three times, and the applicator was placed in a sterile tube. The swabs were rehydrated with 500 µl of sterile water and were vortexed before an aliquot was taken for DNA extraction.
Lymph node aspirates. Retropharyngeal lymph node aspirates were collected while the animals were restrained in a chute. An 18-gauge (1.5-in) needle attached to a 10-ml syringe was inserted into the lymph node, and an aspirate was obtained. Aspirates were transferred to a sterile 15-ml tube and transported on ice. The tubes were vortexed, and a 200-µl aliquot was taken for DNA extraction.
| |
RESULTS |
|---|
|
|
|---|
Duplex amplification (initial setup and optimization).
Experiments for amplification of either M. bovis alone,
B. abortus alone, or the two organisms in combination were
performed with the following genomic DNAs purified from the respective
bacterial cultures: DNAs from 10 M. bovis strains (including
2 TMC strains, 1 BCG vaccine strain, and 7 field isolates), DNAs from 2 M. tuberculosis strains (patient isolates), and DNAs from 5 B. abortus strains (including 2 bovine isolates, type strain
544, and 2 vaccine strains). The amplification conditions and master
mixture components were optimized to amplify all DNAs as singlets or in
different combinations of B. abortus and M. bovis
as duplexes (Fig. 1).
|
Analytical sensitivity estimations. (i) Serially diluted M. bovis and B. abortus amplicons. M. bovis and B. abortus amplicons were generated and column purified (Hi-Pure; Boehringer Mannheim) to remove excess primers. The copy number in each amplicon was determined by using the estimated DNA concentration (calculations were based on the absorbance at an OD of 260 nm and amplicon size). Equal numbers of copies of each amplicon were mixed and serially diluted (2 × 105, 2 × 104, 2 × 103, 2 × 102, and 2 × 101 copies per reaction mixture), and the amplicons were then reamplified. The reamplified amplicons were analyzed by agarose gel electrophoresis and solid-phase probe-capture hybridization and detection as described above. The analytical sensitivity in this amplicon dilution experiment was 20 copies (on the basis of the lowest copy number used in the analysis) for amplicons of both pathogens.
(ii) Serial dilution of B. abortus genomic DNA in milk. One milliliter of normal raw cow milk was spiked with from 200 ng to 0.002 pg of B. abortus DNA (i.e., at equivalents of 2 × 108 to 2 genomes). The copy number (or genome equivalent) estimates were calculated on the basis of the fact that 100 fg of B. abortus DNA is equivalent to 20 organisms (P. H. Elzer, personal communication, 1999). One aliquot of milk was not spiked and was used as a negative control. The DNA was reextracted from the milk by the protocol described above. Forty microliters of the reextracted DNA was amplified as described above and was analyzed on a microtiter plate. By this analysis the analytical sensitivity of the assay was 40 genome equivalents per reaction mixture by microtiter plate detection.
(iii) Serial dilution of B. abortus organisms in milk. Strain 2308 of B. abortus was spiked into a sample of milk at 109 CFU/ml, and the mixture was pasteurized. An aliquot of this was serially diluted (108 to 0 CFU/ml) in raw milk from a healthy cow, and DNA was extracted in 200 µl of distilled deionized water. Ten microliters of this DNA was PCR amplified and was detected by microtiter plate analysis. The results of this analysis indicated that the assay could detect down to 1 × 102 CFU equivalents of B. abortus per reaction mixture (or 2 × 103 CFU equivalents/ml of milk).
Since the results obtained with whole-cell dilutions and genomic DNA dilutions are more accurate than those obtained with amplicons, the analytical sensitivity of the assay was estimated to be 40 to 100 CFU/reaction mixture (or 800 to 2,000 CFU/ml of milk).(iv) Dilution of M. bovis BCG in milk.
An aliquot
of M. bovis BCG was diluted in PBS-Tween 20 (0.05% Tween
20), and the mixture was resuspended to match a McFarland 0.1 standard
(bacterial count equivalent to 4 × 107 CFU/ml). A
total of 100 µl of this suspension was placed in 900 µl of milk
(corresponding to 4 × 107 CFU/ml of milk), and the
mixture was serially diluted to 10
3 CFU/ml. The DNA was
extracted from these dilutions as described above. Subsequently,
amplification and detection were performed as described above.
Assay performance with liver samples from lemmings experimentally infected with B. abortus 2308 or RB51. The assay performance was tested with a set of 45 liver samples from infected lemmings. In total, 33 culture-positive and 12 culture-negative liver samples were tested. Nine of 12 negative samples were from RB51 (an avirulent vaccine strain)-infected lemmings. These samples were interpreted as being from animals that had "cleared" the infection. Of the 33 culture-positive liver samples, 31 were positive by PCR. Therefore, by using culture as a "gold standard," the sensitivity of BPDA-PCR was 93.9% (31 of 33 samples). The two PCR-negative, culture-positive samples were from lemmings infected with the avirulent RB51 strain. Among the 12 culture-negative liver samples, 5 (3 from the strain 2308-inoculated group and 2 from the strain RB51-inoculated group) were identified as positive by PCR, while the other 7 (all RB51 group) culture-negative samples were classified as negative by PCR. These experiments show that the performance of BPDA-PCR may be comparable to that of culture in that BPDA-PCR identified five culture-negative samples from experimentally lemmings as positive. These animals may have incompletely cleared the infection and may thus be carrying damaged organisms that could not be revived by the conventional culturing method used. Additionally, identification of infected animals by culture is often difficult because brucellae are fastidious and slow growers.
Duplex identification of B. abortus and/or M. bovis in milk samples from brucellosis-positive animals sampled in India. DNA was extracted from the milk of 20 cows from a herd in Bangalore, India, known to be infected with B. abortus and was analyzed by BPDA-PCR. Of these 20 milk samples 15 were milk ring test positive (i.e., positive for B. abortus antibodies). The PCR analysis identified 13 of the 15 milk ring test-positive animals and 4 of the 5 milk ring test-negative animals as B. abortus shedders. The ODs at 450 nm ranged from 0.287 to 0.838 and 0.121 to 0.209 for positive and negative samples, respectively. The other negative milk ring test-samples and two milk ring test-positive samples were negative by PCR (Table 1). In addition, upon analysis of these samples by individual probe (M. tuberculosis complex- or B. abortus-specific) hybridization assays, two samples were found to be positive for both B. abortus and M. bovis. All other samples were positive only for B. abortus by BPDA-PCR. These studies further validate the high degree of sensitivity of BPDA-PCR in identifying infected, shedding animals that may be missed by the milk ring test. BPDA-PCR analysis was also able to identify two animals concurrently infected with M. bovis and B. abortus.
Duplex PCR identification of B. abortus and/or M. bovis in milk samples from brucellosis-suspect animals sampled in Argentina. (i) BPDA-PCR performance with suspected M. bovis-positive samples. Thirty-two animals from three purified protein derivative-positive farms were tested. The types of samples tested were milk (n = 32), nasal swabs (n = 22), and retropharyngeal lymph node biopsy specimen (n = 7). Only 1 of 32 milk samples and 2 nasal swabs (from two different farms) were positive for M. bovis (positive OD range, 0.241 to 2.842; negative OD range, 0.067 to 0.192). All lymph node biopsy specimens were negative by tests with both multiple and individual probes. All samples from one farm suspected of being positive were negative.
(ii) BPDA-PCR performance with suspected B. abortus-positive samples.
Twenty-eight milk samples from
brucellosis-positive animals (according to the results of the buffered
antigen plate agglutination [BAPA] test) in two herds were tested.
Seven BAPA test-positive animals tested positive (positive OD range,
0.219 to 0.518; negative OD range, 0.078 to 0.189) by BPDA-PCR and were
defined as B. abortus shedders by analysis with individual
probes (Tables 2 and 3).
|
(iii) BPDA-PCR performance with milk sample pools. Fourteen milk sample pools (with each pool made up of five samples) were analyzed by BPDA-PCR. From retrospective analysis of individual milk samples, it was expected that 6 of the 14 milk sample pools should be positive. BPDA-PCR analysis correctly identified four of six milk sample pools as positive. The two pools in which organisms were not detected were low-positive pools, in that each of these had a sample that was borderline positive (ODs of 0.219 and 0.295, respectively, when individual samples were tested with B. abortus-specific probes). The results indicate that pooling of samples from five animals for BPDA-PCR may miss some low-level shedders or low-level-positive animals. Additional studies with pools of samples from three animals or other combinations will be required to define low-level shedders adequately.
(iv) Internal standard analysis.
A total of 125 samples from
Argentina were tested for amplification of a 226-bp region of bovine
2-microglobulin to determine if any samples contained
PCR inhibitors or if the DNA extraction was functionally intact. All
samples analyzed by agarose gel electrophoresis of the amplicon
products were shown to have single, nondiffuse bands with high
concentrations of amplicons for the
2-microglobulin region of interest. The amplification of the 226-bp region from all
samples indicates no PCR inhibition or DNA degradation; therefore, any
BPDA-PCR-negative sample was considered to be from a nonshedder or to
contain organisms at a level below the detection limits of the assay.
Identification of M. bovis in milk samples or nasal swabs from skin test-positive herds sampled in Mexico. Two sets of samples from Mexico were analyzed. One set consisted of milk samples from animals from caudal fold tuberculin test- and comparative cervical test-positive farms. Forty-six milk sample pools were tested. Each pool was a mixture of milk from 10 individual animals. Of the 46 milk sample pools, 15 were positive (positive OD range, 0.241 to 1.124) with the BPDA-PCR multiplex probe- and M. tuberculosis complex-specific probe-coated microtiter plates. Retrospective analysis of all 10 individual milk samples from one positive pool identified two positive animals. The second set of samples analyzed included nasal swabs (n = 121) obtained from a second geographically distinct area in Mexico. Of the 121 samples, 68 (56.2%) were BPDA-PCR-positive for M. bovis (OD range, 0.406 to 2.882). Animals from these farms were also bovine TB suspect on the basis of intradermal test results.
| |
DISCUSSION |
|---|
|
|
|---|
Economics of disease eradication and the need for an accurate
tool.
The presence of infection caused by the two zoonotic
pathogens, B. abortus and M. bovis, in
animal populations poses an economic threat to countries around
the world (1, 5, 6, 7, 24). This disease has contributed to
nontariff trade barriers by impeding the safe, free trade of cattle and
cattle products implemented by international and other national trade
agreements (6). Losses due to reduced sales and lowered
production and the trade barrier that these diseases have created
reemphasize the need for a rapid, sensitive, specific, and efficient
molecular biology-based diagnostic tool. This would eventually lead to
reduced rates of M. bovis and B. abortus
infection and therefore an increase in the trade, movement, and
marketability of cattle in South, Central, and North America. Countries
in these regions look to the United States for technologies and
protocols that they can use to aid them with their screening for such
zoonoses and to initiate profitable livestock trading across
international borders. On the basis of the prevalence data from the
three countries surveyed (5, 6, 36; Miolan-Suazo et
al., Proc. USAHA Meeting), an algorithm for an eradication program is
proposed (Fig. 2). The algorithm includes
the need for a stepwise, multistage, periodic testing process for a
successful eradication program. The algorithm allows the testing of
milk samples in pools made up of milk from 5 to 10 animals in each pool
in high-incidence areas, thus reducing the cost of screening each
animal. As demonstrated in the samples from Mexico, analysis of pools
made up of 5 to 10 milk samples is feasible and will help identify
positive samples as a part of the proposed eradication algorithm.
|
Current diagnostic practices and their pitfalls. Diagnosis of brucellosis primarily uses the milk ring test or the BAPA test. The milk ring test or the BAPA test has been widely applied for identification of infected herds in the United States and other countries, followed by ELISA, the complement fixation test, or the standard tube agglutination test to confirm infection in individual animals (2, 5, 33). The milk ring test is an agglutination test with fair specificity (79.4 to 86.7%) and sensitivity (85.4 to 99.3%) (32). False-positive results by the milk ring test occur immediately after parturition and during mastitis. Additionally, batch-to-batch variations in milk ring test antigen levels lead to variability associated with the lower sensitivity of the assay (P. H. Elzer, personal communication). The results indicate that the milk ring test may be less sensitive than PCR. On the other hand, while ELISAs have proved to have higher sensitivities and specificities, like the milk ring test they measure antibodies that reflect exposure of the animal to brucellae and do not necessarily indicate present infection or the ability of the animal to spread the disease (5). Despite some of these drawbacks, the two serological tests have been used in successful eradication schemes. Additionally, these tests can be used as an initial screen to identify exposed or infected herds in an eradication program.
PCR with random or selected primers has shown promising results, but large-scale field validations and evaluations are lacking, especially for detection of chronic infections. For PCR, various targets (species-specific, biotype-specific, and genus-specific targets) have been investigated, including the genes for Omp2 (12), the 31-kDa (BCSP31K) antigen (22), the 16S rRNA, the 16S-23S spacer region, and an insertional element, namely, IS711 (3, 4). Among these, the gene that encodes a 31-kDa protein has proved to be a promising target because of the presence of species-specific signature regions in the gene (22). In the past there has been considerable interest in the use of rapid molecular biology-based assays to identify and determine the species of brucellae (3, 4, 5). By using this strategy with species-specific signature regions on Omp2 gene (12), a PCR assay has been developed and patented (T. A. Ficht, B. A. Sowa, and L. G. Adams, May 1994, U.S. patent 5310649). The antigen detection methods are potentially useful but have not been validated. Combinations of these with PCR, such as immuno-PCR, have considerable potential but require evaluation (5). Recent developments in the molecular genetics of mycobacteria have identified species-specific markers in MPT40 (27), oxyR (30), and pncA (9) that enable specific identification of M. bovis. Among these, only the oxyR polymorphism at nucleotide 285 has proved to be an accurate and consistent M. bovis-specific marker (9). Other targets that have been investigated include the 16S rRNA gene region with a TB complex-specific signature sequence, targets identified by randomly amplified polymorphic DNA analysis (18, 26, 28, 29), and mycolic acid profiles identified by the high-performance liquid chromatography (13). The high-performance liquid chromatography method requires a considerable bacterial inoculum, thereby requiring mycobacterial culture, which takes 3 to 6 weeks, before application. It may be argued that IS6110 has more copies and would form a good target for the identification of M. tuberculosis complex organisms. However, numerous ancestral isolates from the M. tuberculosis complex group (especially M. bovis from cattle, goats, or other animal sources and some M. tuberculosis isolates from certain geographic localities that have now spread globally) with no copies of IS6110 exist (31). While the use of oxyR for the specific identification of M. bovis is very attractive, oxyR is a pseudogene in the M. tuberculosis complex; therefore, it is expected under the classical evolutionary theory that this pseudogene may mutate spontaneously (and at a higher rate than other structural genes) over time and may not be detected in some isolates by the use of specific probes. Thus, the hsp65 region with a direct-repeat sequence, which is present in multiple copies, was used in the present study.Performance of BPDA-PCR: experimental and field studies.
The
experiments performed in the present study with purified genomic DNA
optimized the assay for B. abortus identification at <2,000
CFU/ml and for M. bovis identification at <10 CFU/ml. Although the detection level for M. bovis is as low as 4 CFU/ml, we believe that this could be an overestimate due to the
indirect nature of CFU equivalent estimation by the use of McFarland
standards. Overall, experimental studies with either organism proved
that the assay was very sensitive and specific on the basis of the data
obtained for normal and spiked milk samples and liver samples from
experimentally infected lemmings. The performance of BPDD-PCR in field
studies with infected herds from countries that report the occurrence
of the two zoonotic diseases further validates its use as an optimal
tool for surveillance for bovine brucellosis and TB. One of the
concerns with PCR is the occurrence of false-negative results due to
the presence of substances in the sample that interfere with
amplification. The extraction process used in the study efficiently eliminates PCR inhibitors. To test this, all Argentine specimens and a
subset of samples from Mexico were tested for the presence of a
2-microglobulin segment that is highly conserved and
that is expected to be present in host cellular debris of any secretion or excretion. All samples tested positive for
2-microglobulin, thus increasing the degree of
confidence in the technical interpretation of a negative test result as
"negative." On the other hand, false-positive results may occur as
a result of the cross-reactivity of PCR primers and probes or because
of contamination during any stage of collection, processing, and
detection. Therefore, a series of database searches was performed to
identify specific regions for primer and probe design. Additionally,
the study used a hygienic milk collection protocol and laboratory
procedures to minimize cross contamination of samples. This is
reflected by the fact that all negative samples (from disease-free
herds) and controls yielded ODs below the cutoff value.
| |
ACKNOWLEDGMENTS |
|---|
We thank Robert Cooksey (Tuberculosis Laboratory research, National Center for Infectious Diseases, Centers for Disease Control and Prevention) for providing DNA lysates from well-characterized M. bovis and M. bovis BCG strains for this study and for thorough critique of the manuscript. We also thank Pablo Fiero and Oscar Sbodio (SANCOR, Sunchales, Argentina) for help in collecting samples from farms with either brucellosis or bovine TB.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: ClinCyte, LLC, 11055 Flintkote Ave., STE H, San Diego, CA 92121. Phone: (858) 457-9669. Fax: (858) 457-1827. E-mail: bookout8{at}earthlink.net.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Acha, P. N., and B. Szyfres. 1987. Zoonoses and communicable diseases common to man and animals, 2nd ed., p. 24-45. . Scientific publication series no. 503. Pan American Health Organization, Washington, D.C. |
| 2. | Breitmeyer, R. E., D. W. Hird, and T. E. Carpenter. 1992. Serologic and bacteriologic test results after adult vaccination with strain 19 in three dairy herds infected with brucellosis. J. Am. Vet. Med. Assoc. 200:806-811[Medline]. |
| 3. |
Bricker, B. J., and S. M. Halling.
1994.
Differentiation of Brucella abortus bv. 1, 2, and 4, Brucella melitensis, Brucella ovis, and Brucella suis bv. 1 by PCR.
J. Clin. Microbiol.
32:2660-2666 |
| 4. | Bricker, B. J., and S. M. Halling. 1995. Enhancement of brucella AMOS PCR assay for differentiation of Brucella abortus vaccine strains S19 and RB51. J. Clin. Microbiol. 33:1640-1642[Abstract]. |
| 5. | Corbel, M. J. 1997. Brucellosis: an overview. Emerg. Infect. Dis. 3:213-221[Medline]. |
| 6. |
Cornejo, B. J.,
A. Sahagun-Ruiz,
F. Suarez-Guemes,
C. G. Thornton,
T. A. Ficht, and L. G. Adams.
1998.
Comparison of 18-carboxypropylbetaine and glass bead DNA extraction methods for detection of Mycobacterium bovis in bovine milk samples and analysis of samples by PCR.
Appl. Environ. Microbiol.
64:3099-3101 |
| 7. | Cosivi, O., J. M. Grange, C. J. Daborn, M. C. Raviglione, T. Fujikura, D. Cousins, R. A. Robinson, H. F. A. K. Huchzermeyer, I. de Kantor, and F.-X. Meslin. 1998. Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg. Infect. Dis. 4:59-70[Medline]. |
| 8. | Dankner, W. M., N. J. Waecker, M. A. Essey, K. Moser, M. Thompson, and C. E. Davis. 1993. Mycobacterium bovis infections in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine 72:11-37[Medline]. |
| 9. |
Del los Monteros, L. E. E.,
J. C. Galán,
M. Gutiérrez,
S. Samper,
J. F. G. Marín,
C. Martín,
L. Domínguez,
L. de Rafael,
F. Baquero,
E. Gómez-Mampaso, and J. Blázquez.
1998.
Allele-specific PCR method based on pncA and oxyR sequences for distinguishing Mycobacterium bovis from Mycobacterium tuberculosis: intraspecific M. bovis pncA sequence polymorphism.
J. Clin. Microbiol.
36:239-242 |
| 10. | Elzer, P. H., R. W. Phillips, M. E. Kovach, K. M. Peterson, and R. M. Roop, II. 1994. Characterization and genetic complementation of a Brucella abortus high-temperature-requirement A (htrA) deletion mutant. Infect. Immun. 10:4135-4139. |
| 11. | Fekete, A., J. A. Bantle, S. Halling, and M. R. Sanborn. 1990. Preliminary development of a diagnostic test for Brucella using polymerase chain reaction. J. Vet. Diagn. Investig. 69:216-227. |
| 12. |
Ficht, T. A.,
H. S. Husseinen,
J. Derr, and S. W. Bearden.
1996.
Species-specific sequences of the omp2 locus of Brucella type strains.
Int. J. Syst. Bacteriol.
46:329-331 |
| 13. |
Floyd, M. M.,
V. A. Silcox,
W. D. Jones, Jr.,
W. R. Butler, and J. O. Kilburn.
1992.
Separation of Mycobacterium bovis BCG from Mycobacterium tuberculosis and Mycobacterium bovis by using high-performance liquid chromatography of mycolic acids.
J. Clin. Microbiol.
30:1327-1330 |
| 14. | Francis, J., R. J. Seiler, I. W. Wilkie, D. O'Boyle, M. J. Lumsden, and A. J. Frost. 1978. The sensitivity and specificity of various tuberculin tests using bovine PPD and other tuberculins. Vet. Rec. 103:420-425[Medline]. |
| 15. | Frothingham, R. 1995. Differentiation of strains in Mycobacterium tuberculosis complex by DNA sequence polymorphisms, including rapid identification of M. bovis BCG. J. Clin. Microbiol. 33:840-844[Abstract]. |
| 16. | Grange, J. M., M. D. Yates, and I. N. de Kantor. 1996. Guidelines for speciation within the Mycobacterium tuberculosis complex. WHO publication WHO/MC/ZOO/96.4. World Health Organization, Geneva, Switzerland. |
| 17. | Leal-Klevezas, D. S., I. O. Martinez-Vasquez, A. Lopez-Merino, and J. P. Martinez-Soriano. 1995. Single-step PCR for the detection of Brucella spp. from blood and milk of infected animals. J. Clin. Microbiol. 33:3087-3090[Abstract]. |
| 18. |
Linton, C. J.,
H. Jalal,
J. P. Leeming, and M. R. Millar.
1994.
Rapid discrimination of Mycobacterium tuberculosis strains by random amplified polymorphic DNA analysis.
J. Clin. Microbiology
32:2169-2174 |
| 19. | Luzzi, G. A., R. Brindle, P. N. Socket, J. Solera, P. Klenerman, and D. A. Warrel. 1993. Brucellosis: imported and laboratory-acquired cases, and an overview of treatment trials. Trans. R. Soc. Trop. Med. Hyg. 87:138-141[CrossRef][Medline]. |
| 20. | Madkour, M. M. 1989. Brucellosis. Butterworths, London, United Kingdom. |
| 21. | Manthei, C. A., and B. I. L. Deyoe. 1981. Brucellosis, p. 104-121. In H. E. Amstutz (ed.), Bovine medicine and surgery. Veterinary Publications Inc., Santa Barbara, Calif. |
| 22. | Matar, G. M., I. A. Khneisser, and A. M. Abdelnoor. 1996. Rapid laboratory confirmation of human brucellosis by PCR analysis of a target sequence on 31-kDa Brucella antigen DNA. J. Clin. Microbiol. 34:477-478[Abstract]. |
| 23. |
Miller, J.,
A. Jenny,
J. Rhyan,
D. Saari, and D. Suarez.
1997.
Detection of Mycobacterium bovis in formalin-fixed, paraffin-embedded tissues of cattle and elk by PCR amplification of an IS6110 sequence specific for Mycobacterium tuberculosis complex organisms.
J. Vet. Diagn. Investig.
9:244-249 |
| 24. | Nicoletti, P. 1980. The epidemiology of brucellosis. Adv. Vet. Sci. Comp. Med. 24:69-98[Medline]. |
| 25. | O'Reilly, L. M., and C. J. Daborn. 1995. The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tubercle Lung Dis. 76(Suppl. 1):1-46. |
| 26. |
Parra, C. A.,
L. P. Londono,
P. D. Portillo, and M. E. Patarroyo.
1991.
Isolation, characterization, and molecular cloning of a specific Mycobacterium tuberculosis antigen gene: identification of a species-specific sequence.
Infect. Immun.
59:3411-3417 |
| 27. |
Portillo, P. D.,
L. A. Murillo, and M. E. Patarroyo.
1991.
Amplification of species-specific DNA fragment of Mycobacterium tuberculosis and its possible use in diagnosis.
J. Clin. Microbiol.
29:2163-2168 |
| 28. |
Rodriguez, J. G.,
J. C. Fissanoti,
P. D. Portillo,
M. E. Patarroyo,
M. I. Romano, and A. Cataldi.
1999.
Amplification of a 500-base-pair fragment from cultured isolates of Mycobacterium bovis.
J. Clin. Microbiol.
37:2330-2332 |
| 29. | Rodriguez, J. G., G. A. Meija, P. D. Portillo, and M. E. Patarroyo. 1995. Species-specific identification of Mycobacterium bovis by PCR. Microbiology 141:2131-2138[Abstract]. |
| 30. | Sreevatsan, S., P. Escalante, X. Pan, D. A. Gillies III, S. Siddiqui, C. N. Khalaf, B. N. Kreiswirth, P. Bifani, L. G. Adams, T. Ficht, V. S. Perumaalla, M. D. Cave, J. D. A. Van Embden, and J. M. Musser. 1996. Identification of a polymorphic nucleotide in oxyR specific for Mycobacterium bovis. J. Clin. Microbiol. 34:2007-2010[Abstract]. |
| 31. |
Sreevatsan, S.,
X. Pan,
K. E. Stockbauer,
N. D. Connel,
B. N. Krieswirth,
T. S. Whittam, and J. M. Musser.
1997.
Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination.
Proc. Natl. Acad. Sci. USA
94:9869-9874 |
| 32. | U.S. Animal Health Association, Committee on Brucellosis. 1997. Report. U.S. Animal Health Association (www.usaha.org/speeches/caring97.html). |
| 33. | Vanzini, V. R., N. Aguirre, C. I. Lugaresi, S. T. de Echaide, V. G. de Canavesio, A. A. Guglielmone, M. D. Marchesino, and K. Neilsen. 1998. Evaluation of an indirect ELISA for the diagnosis of bovine brucellosis in milk and serum samples in dairy cattle in Argentina. Prev. Vet. Med. 36:211-217[CrossRef][Medline]. |
| 34. |
Vitale, F.,
G. Capra,
L. Maxia,
S. Reale,
G. Vesco, and S. Caracappa.
1998.
Detection of Mycobacterium tuberculosis complex in cattle by PCR using milk, lymph node aspirates, and nasal swabs.
J. Clin. Microbiol.
36:1050-1055 |
| 35. | Weyants, V., J. Godfroid, B. Limbourg, C. Saegerman, and J.-J. Letesson. 1995. Specific bovine brucellosis diagnosis based on in vitro antigen-specific gamma interferon production. J. Clin. Microbiol. 33:706-712[Abstract]. |
| 36. | World Health Organization. 1997. Brucellosis. Fact sheet N173. World Health Organization, Geneva, Switzerland. |
| 37. | World Health Organization. 1986. Sixth report of the Joint FAO/WHO Expert Committee on Brucellosis. WHO Technical report series Rep. 740. World Health Organization, Geneva, Switzerland. |
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||